New Standard of Care For Cancer Detection

Richard (Rick) Mills
Ahead of the Herd

Page 1 of 3

As a general rule, the most successful man in life is the man who has the best information


Most often those who claim to have invented the better mousetrap, real or metaphorically speaking, haven’t - there just isn’t enough of a technological change to force consumers, businesses or institutions to want to, or need to, make a change. Call it incremental technology looking for a market.


The opposite end of the scale would be a change so great, a technological change so much more efficient, so much more attractive a switch is made without question – from 8-tracks to cassettes to CDs. From black and white TV to color. From bulky poor quality movies on VHS tapes to slim, lightweight high quality optics on DVD’s. These examples are all innovations that built upon an existing technology and truly created better mousetraps that were universally accepted as such.


Imagin Medical Inc. (CSE:IME, OTC PINK:IMEXF, Frankfurt/Stuttgart Stock Exchanges:DPD2) has a clear mission.


Bladder cancer has a very high rate of recurrence, one of the highest among the cancers. Because of the high risk of recurrence, patients who have been treated for bladder cancer undergo follow-up endoscopy every 3-6 months. For the rest of the patient’s life, a cystoscopy on a quarterly, semi-annual or annual basis is essential.


Bladder cancer is the most expensive cancer to treat over the lifetime of a patient.



While initially focusing on the US$500M (US$1 billion global) bladder cancer imaging market  in the United States Imagin expects that its dual-light, single-screen imaging system will also set a new standard of care for doctors and surgeons in detecting many other kinds of cancers.


New Standard of Care




The highest level of improvement in any therapy is a “new standard of care.”





Ahead of the HerdSponsors List

No Charge  Newsletter Signup


Newsletter Unsubscribe

To contact us please email

Ahead of the Herd